ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Weizhong Sheng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5083511716. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 2 papers

Papers 2

Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy of Pancreatic Cancer. Co-author DOI 10.1002/smtd.202200888 ↗
NCOR1+/CD4+ T cells in tertiary lymphoid organs suppresses tumor growth and predicts favourable prognosis in pancreatic ductal adenocarcinoma Last author DOI 10.1101/2023.10.15.562444 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tiangeng Dong · 1 shared paper, 2023 · strength 0.22
- Paper NCOR1+/CD4+ T cells in tertiary lymphoid organs suppresses tumor growth and predicts favourable prognosis in pancreatic… DOI 10.1101/2023.10.15.562444 ↗
Yingjie Wang · 1 shared paper, 2023 · strength 0.18
- Paper Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy o… DOI 10.1002/smtd.202200888 ↗
Haijun Yu · 1 shared paper, 2023 · strength 0.18
- Paper Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy o… DOI 10.1002/smtd.202200888 ↗
Feng Wang · 1 shared paper, 2023 · strength 0.18
- Paper Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy o… DOI 10.1002/smtd.202200888 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.